Showing Related Articles
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Journal of Thoracic Oncology, 08/30/2011
Clinical Article
Janku F et al. – Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abrogate cell signaling that perpetuates cancer progression. Critical targets activating procancer pathways include, but are not limited to, epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (MET), vascular endothelial growth factor (VEGF), VEGF receptor, GTPase KRAS (KRAS), receptor tyrosine protein kinase erbB–2 (HER2), echinoderm microtubule–associated protein–like 4–anaplastic lymphoma kinase (EML4–ALK), phosphatidylinositol–4,5–bisphosphate 3–kinase catalytic subunit alpha isoform (PIK3CA), serine/threonine–protein kinase B–raf (BRAF), and insulin–like growth factor 1 receptor (IGF–1R). Some target–directed therapies, such as epidermal growth factor receptor tyrosine kinase inhibitors and anti–VEGF monoclonal antibody, have already been approved for clinical use.
